Kaiser H J, Stümpfig D, Flammer J
University Eye Clinic Basel, Switzerland.
Int Ophthalmol. 1995;19(6):355-8. doi: 10.1007/BF00130854.
Dipyridamole is known to inhibit platelet aggregation and to induce vasodilatation. It has been shown that dipyridamole increases blood flow in various tissues in humans as well as in the eyes of animals. We studied the influence of dipyridamole in a prospective open trial in 23 patients with impaired ocular circulation due to different causes, based on experienced clinical judgement, such as anterior ischemic optic neuropathy, vasospastic syndrome, glaucoma, or central retinal vein occlusion. Blood flow velocities in the ophthalmic artery, central retinal artery and vein, one lateral and one medical posterior ciliary artery were measured using a Siemens Quantum 2000 color Doppler device. Blood flow velocities were measured before and under treatment. Dipyridamole increased blood flow velocities significantly in all vessels measured. Therefore, it seems promising to evaluate the effect of dipyridamole over a longer period in patients with impaired ocular blood flow.
已知双嘧达莫可抑制血小板聚集并诱导血管扩张。研究表明，双嘧达莫可增加人体各种组织以及动物眼部的血流量。我们基于经验丰富的临床判断，对23例因不同原因导致眼循环受损的患者进行了一项前瞻性开放试验，这些原因包括前部缺血性视神经病变、血管痉挛综合征、青光眼或视网膜中央静脉阻塞。使用西门子Quantum 2000彩色多普勒设备测量眼动脉、视网膜中央动脉和静脉、一条外侧睫状后动脉和一条内侧睫状后动脉的血流速度。在治疗前和治疗过程中测量血流速度。双嘧达莫使所有测量血管的血流速度显著增加。因此，在眼血流受损的患者中评估双嘧达莫在更长时间内的效果似乎很有前景。
